House Democrats—including three Squad members—tore into pharmaceutical industry chief executives during a Wednesday congressional hearing on Big Pharma profiteering, with Rep. Katie Porter verbally eviscerating one CEO for more than tripling the price of a critical cancer drug. 

Wednesday marked the first day of a two-day House Oversight Committee hearing titled “Unsustainable Drug Prices: Testimony from the CEOs.” Bristol Myers Squibb CEO Giovanni Caforio, Teva Pharmaceuticals CEO Kåre Schultz, and former Celgene CEO Mark Alles all endured nearly four hours of grilling over the price of prescription drugs—which are almost always far more expensive in the United States than anywhere else in the world.

Porter (D-Calif.), a former consumer protection attorney, was the most ferocious committee member to address the CEOs. Bringing out her infamous white board, she attacked Celgene’s repeated price hikes for the cancer drug Revlimid, which now costs $763 per dose—in 2005 it cost $215. When Alles